1. Home
  2. CDLX vs LUNG Comparison

CDLX vs LUNG Comparison

Compare CDLX & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardlytics Inc.

CDLX

Cardlytics Inc.

HOLD

Current Price

$0.87

Market Cap

69.7M

Sector

Technology

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.58

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDLX
LUNG
Founded
2008
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Industrial Specialties
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.7M
72.2M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
CDLX
LUNG
Price
$0.87
$1.58
Analyst Decision
Hold
Buy
Analyst Count
3
7
Target Price
$2.25
$6.81
AVG Volume (30 Days)
689.8K
355.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.00
EPS
N/A
N/A
Revenue
$278,298,000.00
$83,789,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.01
52 Week Low
$0.80
$1.31
52 Week High
$3.28
$8.72

Technical Indicators

Market Signals
Indicator
CDLX
LUNG
Relative Strength Index (RSI) 40.06 47.44
Support Level $0.83 $1.51
Resistance Level $1.04 $1.69
Average True Range (ATR) 0.09 0.09
MACD 0.01 0.04
Stochastic Oscillator 18.90 68.85

Price Performance

Historical Comparison
CDLX
LUNG

About CDLX Cardlytics Inc.

Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: